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Summary The ability of the anti-oestrogens tamoxifen, toremifene and their 4-hydroxy and N-desmethyl
metabolites to modify doxorubicin (dox) toxicity to intrinsically resistant and multidrug resistant cell lines was
compared, using human breast and lung cancer, and Chinese hamster ovary cell lines. The anti-oestrogens
significantly enhanced dox toxicity to multidrug resistant, P-glycoprotein-positive cell lines, but did not affect
toxicity to intrinsically resistant, P-glycoprotein-negative cells. Modification was observed at clinically
achievable anti-oestrogen concentrations. Toremifene and tamoxifen would therefore appear to be good
candidates for in vivo studies as MDR modulating agents in selected patients with P-glycoprotein-positive
tumours.
Doxorubicin (dox) is cytotoxic to many solid tumours and
anthracyclines are the most active single agents available for
the treatment of advanced breast cancer, with response rates
of 43% in previously untreated and 28% in previously
treated patients (Tormey, 1975). Unfortunately, chemo-
therapy is not curative in these patients, and the development
ofdrug resistance is a major problem in clinical management.
Tumour cells may become resistant not only to the drug to
which they were initially exposed, but also to a range of
structurally and functionally unrelated compounds. This
phenomenon, known as multidrug resistance (MDR), fre-
quently coincides with expression of a 170kDa membrane
glycoprotein (the mdrl gene product, P-glycoprotein; End-
icott & Ling, 1989). Increased levels of P-glycoprotein (Pgp),
associated with resistance to dox and vinblastine, have been
detected in a number of human tumours, including breast
cancers in patients previously treated with chemotherapeutic
drugs (Sanfilippo et al., 1991). MDR-positive cells generally
accumulate less drug than their sensitive counterparts
(Kessel, 1986; Foster et al., 1988), and the structure of Pgp
indicates it may act as an ATP-dependent 'drug efflux pump',
reducing intracellular drug concentrations to sub-lethal levels.
The mdrl gene product has also recently been shown to be
'associated' with a volume-activated chloride channel (Val-
verde et al., 1992), and is a member of the ABC (ATP
binding cassette) superfamily of ATP-dependent active trans-
porters of which over 40 members have so far been charac-
terised (Higgins, 1989). The superfamily includes bacterial
transport proteins and the cystic fibrosis transmembrane con-
ductance regulator, CFTR (Higgins & Hyde, 1991). Cells
expressing the MDR phenotype are typically cross-resistant
to large lipophilic 'natural product' cytotoxins such as dox
and the Vinca-alkaloids, but not to anti-metabolites or
alkylating agents.
Circumvention of MDR could be of great clinical benefit,
and many potential resistance modifiers have been evaluated.
The calcium channel blocker verapamil was the first to be
identified and was shown to enhance vincristine toxicity to
MDR-positive P388 leukaemia (Tsuruo et al., 1981). A
photo-affinity analogue ofverapamil with no calcium channel
antagonist activity binds Pgp (Qian & Beck, 1990), indicating
that the MDR-modulating activity of verapamil is due to
competitive inhibition of Pgp at specific drug binding sites,
resulting in inhibition of drug efflux (Kessel, 1986). Indeed,
many MDR modifiers have been demonstrated to enhance
intracellular drug accumulation in Pgp-positive cells (Ramu
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et al., 1984; Kessel, 1986), although the increases in drug
concentration observed rarely exceed 2- to 3-fold and may
not be sufficient to explain the large enhancements of drug
toxicity demonstrated (Fairchild & Cowan, 1991). Unfor-
tunately, levels of verapamil achievable in vivo only border
on those required to modify drug resistance in vitro and
attempts to modulate resistance, particularly in solid
tumours, have been relatively unsuccessful. Other compounds
demonstrated to enhance drug toxicity to MDR-positive cell
lines include calmodulin antagonists (e.g. trifluoperazine;
Ganapathi et al., 1991), immuno-suppressants (e.g. cyclo-
sporin A; Twentyman et al., 1987) and the anti-oestrogens
tamoxifen (Ramu et al., 1984) and toremifene (DeGregorio et
al., 1989).
Tamoxifen and toremifene are used to treat breast cancer,
and their ability to bind oestrogen receptors (ER) is well
documented (Lerner & Jordan, 1990; Kangas, 1990). Both
anti-oestrogens are well tolerated, although toremifene can be
administered at higher doses (Kohler et al., 1990; Robinson
et al., 1990), and higher plasma concentrations can therefore
be achieved (DeGregorio et al., 1989; Kaye, 1990). Tamox-
ifen and toremifene are metabolised extensively in vivo,
primarily to the N-desmethyl, N-didesmethyl and 4-hydroxy
derivatives (Jordan et al., 1983); Kangas, 1990; Kaye, 1990;
Robinson et al., 1991). These metabolites differ from their
parent compounds in their biological activity; for example,
4-hydroxy tamoxifen (OHTx) has 100-fold greater affinity for
ER than tamoxifen (Jordan et al., 1980). The cytotoxic and
MDR-modulating activity of tamoxifen, toremifene and their
major metabolites should therefore be thoroughly inves-
tigated if these compounds are to be seriously considered as
potential in vivo modifiers of MDR.
The effects of tamoxifen, toremifene and their two major
metabolites on cell growth and on dox toxicity have been
studied. The panel of cell lines used includes three Pgp-
positive MDR cell lines and their drug-sensitive parental lines
(Table I). In addition, a range of human breast and lung
cancer cell lines of varying histological type were included in
this study. They differ markedly in intrinsic sensitivity to dox,
and this effect is unrelated to P-glycoprotein expression.
Materials and methods
Cell lines and tissue culture
Wild type cell lines and their drug-resistant sublines used in
this study were (i) the human non-small cell lung carcinoma
S1 (Baas et al., 1990) and its mdrl-transfected subline S1/1.1
which has mdrl levels at least 100-fold higher than the wild
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Table I Characteristics ofcell lines
Densit/a Antibody stainingb
Cell line Characteristics References (cells/well) MRK16 C219
CHO
CHO-Ki Wild type Puck et al. (1958) 1,000 + -/+
CHO-KlAdr MDR + ve Chatterjee & Harris (1990) 1,000 + +
Breast cancer
MCF-7 ER + ve Soule et al. (1973) 5,000 - -1+
MCF-7Adr ER -ve, MDR + ve Batist et al. (1986) 5,000 + + +/+ + +/+
MDA-468 ER -ve Cailleau et al. (1974) 5,000
T47D ER + ve Freake et al. (1981) 5,000 - +
Lung cancer
S1 Non-small cell Baas et al. (1990) 1,500
Si/1.1 mdrl-transfectant Baas (unpublished, 1991) 1,500 +/+ + +
NCI-H 322 Bronchio-alveolar Carmichael et al. (1987) 10,000 - -
NCI-H 358 Bronchio-alveolar Carmichael et al. (1987) 10,000 - -
NCI-H 460 Large cell Carmichael et al. (1987) 1,000 - -
NCI-H 841 Small cell (variant) Carmichael et al. (1987) 10,000 - -
b aDensity at which cells were plated in wells of 96 well microtitre plates for cytotoxicity assays. bCells were
stained with anti-Pgp monoclonal antibodies MRK16 and C219 as described in Materials and methods.
Strong positive staining (+++ +); positive staining (+ +); weak staining (+); negative staining (-);
heterogeneous results e.g. most cells strongly positive with others weakly positive (++ +/+).
type cell line (Dr F. Baas, personal communication), (ii) the
human breast cancer cell line MCF-7 (Soule et al., 1973) and
its dox resistant subline MCF-7Adr (Batist et al., 1986) and
(iii) the Chinese hamster ovary cell line CHO-KI (Puck et al.,
1958) and its dox resistant sub-line CHO-KIAdr (Chatterjee &
Harris, 1990). S1 and SI/1.1 cells were kindly provided by Dr
F. Baas (University of Amsterdam, The Netherlands), other
lung cancer cell lines by Dr A.F. Gazdar (NCI Navy Medical
Oncology Branch, Bethesda, USA) and MCF-7 and MCF-7Adr
breast cancer cell lines by Dr K. Cowan (NCI Clinical Phar-
macology Branch, Bethesda, USA).
All cell lines were maintained as monolayer cultures in
HAMS F12 medium (S1, S1/1.1, CHO-KI and CHO-KlAdr)
or RPMI 1640 medium (all other cell lines), each sup-
plemented with 10% foetal calf serum and 2 mM glutamine.
Cultures were grown in 5% CO2 under 100% humidity at
37°C and maintained in exponential growth phase by passag-
ing twice weekly. All cell lines were regularly shown to be
Mycoplasma-free, and are listed in Table I.
Drugs
Dox, formulated for clinical use (Farmitalia UK, St Albans),
was stored as a 5 mM solution in normal saline at - 20°C
and diluted as required in saline. Tamoxifen and metabolites
were provided by ICI Pharmaceuticals (Macclesfield, UK)
and toremifene and metabolites by Orion Corporation
(Turku, Finland). Tamoxifen was prepared as a 50 mm stock
solution in ethanol and stored at 4°C. N-desmethyl tam-
oxifen (NdMTx), OHTx, toremifene, N-desmethyl toremifene
(NdMTf) and 4-hydroxy toremifene (OHTf) were dissolved
in DMSO to give 50 mM stock solutions, which were diluted
as required in PBS. Anti-oestrogens were tested in each cell
line at a range of concentrations (0.5, 1, 2, 5, 10, 20, 25, 30,
50 and 100 !M). The highest level which was reproduceably
found to alter control cell optical density by less than 5%
was defined as the maximum non-toxic concentration (MNC,
listed in Table II), and this concentration was used in drug
toxicity modification experiments. Organic solvent levels did
not exceed 0.1% by volume of the cell suspension, a concen-
tration of vehicle demonstrated not to affect cell growth.
Cytotoxicity assavs
Exponentially growing cells were trypsinised, centrifuged and
resuspended in fresh medium (10% FCS, 2 mM glutamine) at
the appropriate cell density. Cell suspension (180 1tl) was
aliquoted into 96 well microtitre plates at a seeding density
previously demonstrated to allow exponential growth for 4
days. Anti-oestrogen modifiers, dox and/or vehicle (10 ,Il)
were added in quadruplicate at appropriate concentrations.
Cells were incubated continuously with drug and/or modifier
at 37°C (5% C02, 100% humidity) for 4 days. Cytotoxicity
was determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide] assay (Mosmann, 1983;
Carmichael et al., 1987). MTT (50 jil, 2 mgml-') was ali-
quoted into all wells and the cells incubated for a further 4 h.
Plates were inverted to discard medium and formazan cry-
stals solubilised in 100y1 DMSO with 25 gl glycine buffer
(0.1 M glycine in 0.1 M NaCl, pH 10.5; Plumb et al., 1989).
Plates were agitated for 5 min, and optical densities deter-
mined immediately at 540 nm using a Titertek Multiskan
Plus MKII ELISA plate reader. Data were analysed using
Deltasoft Elisa Analysis software (BioMetallics Inc.,
Princeton, NJ).
Cytotoxicity was expressed as the IC50 value; the concen-
tration of drug causing a 50% reduction of control cell
optical density. ICm values are presented as the mean of
those determined from at least six experiments ± the stan-
dard error of the mean (s.e.m.). The number of repeats is
indicated in the Table and Figure legends. IC50 values deter-
mined in the presence and absence of anti-oestrogens were
compared using paired t-tests. Modification of dox toxicity
by anti-oestrogens was expressed as a modification factor
(MF), calculated by dividing the dox IC50 value determined
in the absence of anti-oestrogen by that determined in the
presence of anti-oestrogen. A MF value of 1 therefore
indicates that anti-oestrogens do not affect dox toxicity, while
values greater than 1 indicate enhancement of, and values
less than 1 protection from, dox toxicity.
Table II Sensitivity of cell lines to tamoxifen and toremifene. Anti-
oestrogen IC50 values are mean values from 6 determinations ± s.e.m.
Anti-oestrogen IC50 (jsM)
Cell line Tamoxifen Toremifene MNC (fM)a
CHOKI 20±4 18±2 10
CHO K1Adr 16 2 14 1 10
MCF-7 11 1 12±1 1
MCF-7Adr 31 2 27 1 20
MDA-468 15±2 15 1 10
T47D 19±2 18 1 5
S1 22±2 23 1 10
Sl/l.1 21 1 21 2 10
NCI-H 322 27 3 25 1 10
NCI-H 358 26±2 27 2 10
NCI-H 460 14 2 15 2 5
NCI-H841 28±3 27±2 10
'MNC (maximum non-toxic concentrations) are the same for all
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Immunocytochemical staining
Cells in exponential growth phase were removed from flasks
by trypsinisation, washed three times with PBS and
resuspended in PBS to a density of 105 cells ml-'. Cell
suspension (0.5 ml) was applied to microscope slides by
cytospinning. Cells were incubated first with a monoclonal
antibody (MRK16 or C219) for 30 min, then with per-
oxidase-conjugated rabbit anti-mouse Ig (Dakopatts, Glos-
trup, Denmark). The peroxidase reaction was developed
using diaminobenzidine (Sigma Chemical Co.) and hydrogen
peroxide.
Results
Cell lines were stained with monoclonal antibodies, MRK16
and C219, which recognise different epitopes of Pgp. In
general, similar results were obtained with both antibodies,
although MRK16 stained cells more strongly (Table I). Both
antibodies stained MCF-7Adr cells positively for Pgp with
-70% of cells showing very strong staining, while MCF-7
cells stained weakly with C219 only. CHO-KlAdr cells were
positive for Pgp with both antibodies. CHO-K1 cells stained
weakly and uniformly with MRK16, while d40% of cells
stained with C219. The mdrl transfectant Sl/1.1 was positive
with both antibodies, with - 5% of cells staining more
strongly with MRK16, and wild type SI cells were Pgp-
negative with both antibodies. Results for the remaining wild
type lung and breast cancer cell lines were negative or weakly
positive and are summarised in Table I.
Tamoxifen and its structural analogue toremifene were
equitoxic (Table II). The metabolites of these anti-oestrogens
had similar toxicities to their parent compounds (data not
shown), although their reported affinities for ER vary (Jor-
dan et al., 1980). ER-positive MCF-7 cells were most sen-
sitive to anti-oestrogens, exhibiting biphasic dose response
curves, while ER-negative cell lines were in general more
resistant, with steep, monophasic dose response curves (data
not shown). Although the MCF-7Adr cell line was more resis-
tant to anti-oestrogens than its ER-positive parental line, the
remaining MDR-positive cell lines were not, indicating that
such resistance is not part of the MDR phenotype.
MCF-7Adr cells were 180-fold resistant to dox relative to
wild type MCF-7 cells (Table III). Figure 1 shows the effect
of tamoxifen on dox toxicity to wild type MCF-7 and MCF-
7Adr cells. Increasing concentrations of tamoxifen (up to a
MNC of 20pM) shifted the dox dose response curve for
MCF-7Adr cells progressively leftwards, indicating enhance-
ment of drug toxicity, while similar dose response curves for
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Table III Effects of anti-oestrogens on dox toxicity to MCF-7 and
MCF-7Adr breast cancer cells. Dox ICm values are presented as mean
values from 10 determinations ± s.e.m.
Dox IC50 value (nM)
MCF-7 MCF-7Adr
Modifier + Modifierw MF + Modifier MF
None 64±5 - 11600±1100
Tamoxifen 70 10 o.gb 1410 230 8.2***
OHTx 71 18 0.9 1020 80 11.4***
NdMTx 60 7 1.1 2320 330 5.0***
Toremifene 74± 11 0.9 972± 146 11.9***
OHTf 58 10 1.1 853 121 13.6***
NdMTf 82 17 0.8 1300 230 8.9***
aAnti-oestrogens were added to cells at the appropriate MNC (Table
II). bWhere MF= 1, P values of 0.05-1.0 were obtained.
***P 0-0.001.
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Figure 2 Effect of anti-oestrogens on dox toxicity to MCF-7Adr
cells. Modification of dox toxicity is expressed as a modification
factor (ratio of dox ICm values determined in the absence and
presence of modifier). Tamoxifen (0), OHTx (A), NdMTx (-),
toremifene (0), OHTf (A) and NdMTf (0). Results are mean
MF calculated from ten identical experiments ± s.e.m.
100
Figure 1 Effect of tamoxifen on dox toxicity to a, wild type MCF-7 and b, MDR-positive MCF-7Adr cells (results from one
representative experiment). a, 0 (0), 0.1(O), 0.5 (A) and I isM (A) tamoxifen; b, 0 (0), 1 (0), 10 (A) and 20ZlM (A) tamoxifen.
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wild type MCF-7 cells overlayed, indicating that tamoxifen
had no effect on drug toxicity. However, it should be noted
that the MNC of anti-oestrogens for MCF-7 was 1 pm, a
dose causing no significant modification of dox toxicity to
either cell line. The effects of anti-oestrogens were not altered
by addition of oestradiol (unpublished data). The effects of
the MNC of tamoxifen, toremifene and their metabolites on
dox toxicity to wild type MCF-7 and MCF-7AId, cells are
summarised in Table III. All anti-oestrogens significantly
enhanced dox toxicity to Pgp-positive MCF-7AId, cells (5- to
14-fold), but had no effect on wild type cell sensitivity. The
relative efficacy of the anti-oestrogens as modifiers of dox
toxicity to MCF-7AId, cells is compared in Figure 2, where the
degree of modification observed is expressed as a function
of anti-oestrogen concentration. Modification of dox toxicity
was clearly a dose-dependent effect, although curves plateaued
as anti-oestrogen concentrations approached 20 .tim. All com-
pounds significantly enhanced dox toxicity and OHTf was
apparently the most effective modifier at all concentrations.
The maximum modification observed was a 14-fold reduction
in the lCm value from 11.6flm to 0.85 JLm in the presence of
20tLm OHTf, a value still 13-fold in excess of that obtained
for wild type cells (0.064ltm); sensitivity was not reduced to
wild type levels.
Wild type MCF-7 cells were more sensitive to anti-
oestrogens than MCF-7AId, cells, and equimolar doses of
modifiers therefore could not be compared. The effects of
tamoxifen and toremifene on dox toxicity to wild type
CHO-Ki and MDR-positive CHO-KIAdr cells, which are
equally sensitive to anti-oestrogens, were therefore deter-
mined. CHO-KlIAd, cells showed a marked (18-fold) resis-
tance to dox relative to its parental line, CHO-KI.
Tamoxifen and toremifene (10pEm) enhanced dox toxicity to
the wild type cell line 3- and 4-fold, respectively, but caused
more substantial 7- and 9-fold increases in toxicity to CHO-
KlAdr cells (Table IV). Lesser modifications were observed
with 5 pM tamoxifen and toremifene. A mean 7-fold degree
of resistance therefore remained between MDR-positive and
wild type cells in the presence of anti-oestrogens.
Surprisingly, the lung cancer cell lines SI and the mdrl
transfectant S1/1.1 were equally sensitive to dox (although
Sl/l.1 cells were 5-fold resistant to vinblastine relative to SI
cells, unpublished data), despite different levels of mdrl ex-
pression. Dox toxicity to wild type cells was not enhanced by
tamoxifen and toremifene, however a slight but significant
degree of modification (2-fold; P<0.01) was observed for
the transfectant, to below wild type sensitivity (Figure 3,
Table IV).
The effects of anti-oestrogens on dox toxicity to Pgp-
negative cell lines were further investigated by determining
dox toxicity to 6 MDR-negative lung and breast cancer cell
lines; lCm values ranging from 22 to 335 nm were deter-
Table IV Effects of tamoxifen and toremifene on dox toxicity to CHO, lung cancer and
breast cancer cell lines. Dox IC50 values are presented as the mean of at least 6
determinations ± s.e.m.
Dox IC50 value (nm)
Cell line + PBS + Tamoxifena MF + Toremifenea MF
CHO-Ki 76±6 29±+5 2.6** 17±+2 4.*
CHO-KIAdT 1360 ±140 182 ± 37 7.5** 145 ± 37 94*
Si 71±4 65±3 11b 62±4 1.1
51/1.1 61±6 37±3 1.6** 30±320*
MCF-7c 64±5 70+10 0.9 74±11 0.9
MCF-7Adrc 11600±1100 1410±230 8.2*** 972± 146 jj*.9***
MDA-468 182±8 170±11 1.1 180±3 1.0
T47D 187±30 236± 14 0.8 206±22 0.9
NCI-H322 335±64 343±15 1.0 387±53 0.9
NCI-H358 169±7 156±46 1.1 158±30 1.1
NCI-H460 22±2 25±2 0.9 21±2 1.0
NCI-H841 118±6 115±9 1.0 117±13 1.0
aTamoxifen and toremifene were added to cells at theappropriate MNC (TableII).bWhere
MF = 1, P values of 0.05 -1.0 were obtained. 'These data duplicated from Table 11I. *P 0.01 -0.05. **P=0.00l -0.01. ***P=~ 0 .001.
a
I'I U i v
I
0 1 10 100 100
I I ~i- i
I I
1 10 100 1000
[Doxorubicin] (nm)
Figure 3 Effect of 0 (@), 1(0), 5 (A) and 0 jLm (A) tamoxifen on dox toxicity to a, wild type SI and b, mdrlI-transfected S1I/1.1I
cells (results from one representative experiment).
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mined. The effects of the MNC of tamoxifen and toremifene
(5 and 10t4M) on drug sensitivity was investigated (Table IV).
Dox toxicity in the presence and absence of anti-oestrogens
was not significantly different, indicating that no modification
of drug toxicity was achieved.
Discussion
Despite their different affinities for ER, tamoxifen, toremifene
and their metabolites were equitoxic to a range of breast and
lung cancer cell lines. This results differs from that described
by DeGregorio et al. (1989), who found MCF-7Adr cells to be
more sensitive to OHTx and NdMTx than to tamoxifen.
Cytotoxicity was assessed using methylene blue staining after
48 h exposure to anti-oestrogens. Differences between their
results and those presented here may arise from different
assay systems employed. Tamoxifen, toremifene and their
metabolites are structurally similar, and it is perhaps not
surprising that toxicity to ER-negative cells does not
vary greatly between these compounds. Higher resistance of
MCF-7Adr cells to anti-oestrogens relative to wild type MCF-7
cells was probably due to different ER status rather than mdrl
expression; CHO-KI and CHO-KlAdr cells were equally sen-
sitive to anti-oestrogens, as were Sl and Si/1.1 cells. Resis-
tance to anti-oestrogens therefore does not appear to be char-
acteristic of the MDR phenotype, consistent with the report by
Kessel (1986) that tamoxifen is not transported by Pgp.
Tamoxifen and toremifene substantially modified dox
toxicity to Pgp-positive CHO-K1Adr and MCF-7Adr cells.
Modification of dox toxicity by anti-oestrogens occurred
irrespective of ER status and was unaffected by oestradiol
(unpublished data), indicating that enhanced dox toxicity is
not an anti-oestrogenic effect. In fact, substantial mod-
ification of drug toxicity is more likely to be observed with
ER-negative cell lines which can tolerate higher doses of
anti-oestrogens, because MDR-modification occurs in a dose
dependent manner (Figure 2).
No enhancement of dox toxicity to MDR-negative lung
and breast cancer cell lines exhibiting a 15-fold range of
sensitivities to the drug was observed and modification of
drug toxicity by anti-oestrogens would therefore appear to be
an MDR-specific effect. However, dox toxicity to CHO-KI
cells was enhanced. Gupta (1988) demonstrated that wild
type CHO cells display intrinsic resistance to drugs associated
with MDR, which can be reversed by verapamil. CHO-Kl
cells stained weakly with anti-Pgp antibodies (Table I), and
intrinsic MDR in CHO cells may therefore be mediated by
Pgp. This is supported by the discovery that Pgp is associated
with a volume-activated chloride channel (Valverde et al.,
1992), as CHO cells are known to respond to increases in
volume with enhanced chloride channel activity (Sarkadi et
al., 1984).
The ability of tamoxifen, toremifene and their metabolites
to modify dox resistance in MCF-7Adr cells was compared.
Maximal modification of MDR was observed at 10-20tM.
The relative ranking of efficacy for both tamoxifen and
toremifene appeared to be: hydroxy metabolites>parent
compounds>N-desmethyl metabolites. DeGregorio et al.
(1989) also observed modulation of dox toxicity to MCF-7Adr
cells by toremifene and its metabolites, but found OHTf to
be less effective than toremifene and NdMTf. Differences
between their results and those presented here may arise from
differences between experimental procedures. DeGregorio
and co-workers described synergy between toxic concentra-
tions of anti-oestrogens and a single (toxic) dose of dox
(1 uM), whilst in the present study, the effects of non-toxic
doses of anti-oestrogens on a range of dox concentrations
were determined. The ability of anti-oestrogen metabolites to
reverse drug resistance is highly significant as these com-
pounds are major products of tamoxifen and toremifene
metabolism. Steady state serum levels of N-desmethyl and
4-hydroxy metabolites are, respectively, - 140% and -33%
parent compound levels in patients receiving tamoxifen (Lien
et al., 1989) and '400% and -25% in patients treated with
toremifene (DeGregorio et al., 1989; Kohler et al., 1990).
Overexpression of Pgp is generally associated with
decreased intracellular drug concentration, and there is
evidence that anti-oestrogens increase drug accumulation in
MDR-positive cells (Kessel, 1986; Ramu et al., 1984). For
example, 10 LM tamoxifen caused a - 3-fold increase in
daunorubicin accumulation in the MDR-positive cell lines,
HL-60/RV + and CEM-VBL, but did not alter intracellular
drug levels in wild type lymphoblastic leukaemia CEM cells
or in myeloid leukaemia HL60 cells (Berman et al., 1991).
The mechanism by which anti-oestrogens alter cellular drug
retention is not fully understood. Tamoxifen inhibits protein
kinase C (PKC) (O'Brian et al., 1985; Su et al., 1985; Horgan
et al., 1986), an enzyme implicated in the phosphorylation
and concomitant activation of Pgp (Chambers et al., 1990).
Inhibition of PKC by staurosporine reduces Pgp phosphory-
lation, increases daunorubicin accumulation and enhances
drug toxicity in MDR-positive HL-60 cells (Ma et al., 1991).
Staurosporine also increases vincristine accumulation in
MDR-positive human myelogenous leukaemia (K562/ADM)
cells (Sato et al., 1990). Tamoxifen may therefore modulate
MDR through inhibition of PKC, leading to inactivation of
Pgp and enhanced drug accumulation. However, while
NdMTx is the most active inhibitor of PKC (O'Brian et al.,
1988) it is the least effective modifier of MDR in the present
study.
Tamoxifen is also a calmodulin antagonist (Lam, 1984)
and it has been suggested that this activity may be responsi-
ble for modulation of MDR (Chatterjee & Harris, 1990).
However, Tsuruo et al. (1982) compared the effects of a
range of calmodulin inhibitors on the accumulation and tox-
icity ofvincristine and dox to MDR-positive P388 leukaemia,
and found no correlation between antagonism of calmodulin
and either drug accumulation or modulation of drug toxicity.
Hindenburg et al. (1987) report intra-lysozomal localisa-
tion of dox in dox-resistant HL60/AR, but not in drug
sensitive HL60 cells. They suggest a wide range of resistance
modifiers (e.g. chloroquine, clomiphene, tamoxifen, vera-
pamil) alter drug solubility in subcellular compartments,
allowing drug to redistribute within the cell and gain access
to intracellular targets.
Interestingly, dox was equally toxic to the non-small cell
lung carcinoma cell lines S1 and S1/1.1, although the mdrl-
transfected cells were shown to be Pgp-positive with antibody
staining (Table I). The low levels of resistance in S1/1.1 cells
described in this study are typical of some mdrl transfec-
tants, and occur despite elevated levels of Pgp expression.
Fairchild et al. (1990) transfected wild type MCF-7 cells with
the mdrl gene isolated from its MDR-positive subline, MCF-
7Adr and achieved levels of Pgp in transfectants equal to, or
exceeding, those observed in MCF-7Adr cells. However,
although the same pattern of MDR was displayed, the trans-
fected cells did not exhibit the high degree of resistance
observed in MCF-7Adr cells. It therefore appears that while
expression of mdrl can confer the MDR phenotype, it is not
sufficient to generate the very high levels of resistance
observed in cell lines which have been exposed to high drug
concentrations in vitro. The possible interaction between
PKC and Pgp has been discussed above. PKC levels are
frequently elevated in highly resistant MDR-positive cells
(Fine et al., 1988) and may be necessary for activation of Pgp
and expression of the full MDR phenotype.
It is also apparent that chronic drug-treatment activates
multiple, independent mechanisms of resistance. Dox exerts
multiple cellular effects, including topoisomerase II inhibition
(Tewey et al., 1984), DNA binding (Neidle, 1979), membrane
disruption (Tritton, 1991) and production of oxygen radicals
(Bachur et al., 1979), and may induce resistance via any of
these pathways.
Patients treated with tamoxifen or toremifene accumulate
stable serum concentrations of parent compounds and
metabolites (Kohler et al., 1990; Langan-Fahey et al., 1990).
Patients receiving 'high dose' tamoxifen therapy (480 mg/day,
Stuart et al., 1992) achieved plasma tamoxifen levels of
3.5JIM, while total levels of tamoxifen and metabolites were1194 J. KIRK et al.
- 7tLM. Although anti-oestrogens have been demonstrated to
be -99% bound to plasma proteins such as alpha, acid
glycoprotein (Chatterjee & Harris, 1990), these compounds
are lipophilic cations and it is therefore likely that they
accumulate to higher concentrations within the cell. Lien et
al., (1991) determined anti-oestrogen levels in patients treated
with 20-80 mg tamoxifen daily. A mean serum tamoxifen
concentration of 0.2fLM was achieved; however, mean levels
in brain were 4.5 ttM and in metastases, 6.6 JiM. The same
trend was observed with NdMTx and OHTx, and on average
the concentration of anti-oestrogen accumulated in tissues
was 16- to 30-fold higher than in serum. The total concentra-
tion of tamoxifen, OHTx and NdMTx achieved in metastases
was - 16gM, a concentration of anti-oestrogen which would
enhance dox toxicity to MCF-7Adr cells - 7-fold in vitro. This
result suggests that 'low dose' therapy may generate anti-
oestrogen levels sufficient to modulate MDR in vivo. Alterna-
tively, if the same degree of compartmentalisation between
serum and tissues occurs during high dose tamoxifen treat-
ment, very high intracellular anti-oestrogen concentrations
may be reached, and significant enhancement of cytotoxic
drug action could be achieved.
Tamoxifen, toremifene and their 4-hydroxy and N-
desmethyl metabolites are effective in vitro modifiers of MDR
at achievable serum concentrations. They are clinically well-
tolerated and may therefore be of great benefit in the treat-
ment of tumours which characteristically express high levels
of Pgp, such as renal, colorectal and adrenal carcinomas.
However, it should be stressed that little effect was observed
in intrinsically resistant MDR-negative cell lines, making
patient selection an important parameter in the clinical
evaluation of this class of modifier.
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toremifene; OHTx, 4-hydroxy tamoxifen; PBS, phosphate-buffered
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